Phenotypic and biochemical characteristics and molecular basis in 36 Chinese patients with androgen receptor variants

Hui Zhu1†, Haijun Yao2†, Yue Xu1†, Yan Chen3†, Bing Han1, Nan Wang1, Hao Wang1, Qiang Zhang1, Wenjiao Zhu1, Yuanping Shi1, Hua Sun3, Shuangxia Zhao4, Huaidong Song4, Yang Liu5* and Jie Qiao1*

Abstract

Background: Androgen insensitive syndrome (AIS) is a rare genetic disease resulting from androgen receptor (AR) mutations and one of the causes of 46, XY disorder of sexual development (DSD). This study aimed to describe the clinical features and molecular defects of 36 Chinese patients with AR variants and investigate the functional alterations of novel variants in vitro.

Material and methods: Subjects with AR variants were identified from 150 Chinese 46, XY DSD patients using targeted next-generation sequencing. In-silico and functional assays were performed to evaluate the transcriptional activity and nuclear localization of novel AR variants.

Results: Eight novel and fifteen reported AR variants were identified. 30.6% (11/36) of patients harbored additional variants other than AR. Mutations in the Arg841 residue were found in 7 unrelated patients. Postpubertal serum gonadotropin levels were significantly elevated in patients with complete AIS (CAIS) compared with those in patients with partial AIS (PAIS) (P < 0.05). All the novel variants initially predicted to be uncertain significance by in-silico analyses were reclassified as likely pathogenic for defective AR transcriptional activity in vitro, except p.L295P, which was found in an atypical patient with oligogenic mutations and reclassified as likely benign. c.368_369 ins T was observed to interfere with nuclear translocation.

Conclusions: Compared with PAIS patients, postpubertal CAIS patients had higher gonadotropin levels. Arg841 was disclosed as the location of recurrent mutations in Chinese AIS patients. Functional assays are important for reclassifying the novel AR variants and re-examining the diagnosis of AIS in specific patients with oligogenic mutations, instead of in-silico analysis.

Keywords: Androgen insensitive syndrome (AIS), Androgen receptor (AR) mutation, Disorder/differences of sex development (DSD), Functional assay
AIS (CAIS), with the complete feminization of the external genitalia; partial AIS (PAIS), with a variable clinical presentation; and mild AIS (MAIS), with normal male external genitalia but gynecomastia and/or infertility in puberty or adulthood [2]. As a rare genetic disease, the incidence of AIS varies among different ethnic backgrounds and ranges between 1:20,000 and 1:99,000 in genetically 46, XY males [4].

The process of male sexual differentiation and maturation is strictly related to androgen and normal androgen receptor (AR) function [5]. AR is a nuclear receptor and allows target cells to respond to the biological action of androgen by binding testosterone (T) or dihydrotestosterone (DHT) [4], which is critical for the physiological virilization of male genitalia that occurs between the 8th and 14th weeks of gestation [6]. AIS is an X-linked recessive disorder caused by pathogenic mutations in the AR gene that lead to complete or partial resistance to the physiological effects of androgen in 46, XY individuals [7].

The AR gene (NR3C4) is located at chromosome Xq11-12 and consists of eight exons [8]. The entire receptor consists of three functional domains: the variable N-terminal domain (NTD), the conserved DNA-binding domain (DBD) and the conserved C-terminal ligand-binding domain (LBD) [9, 10]. To date, there are more than 800 reported mutations in the AR gene related to AIS [11], most of which were predicted to be pathogenic by in-silico analyses. However, these bioinformatic tools tend to show low specificity, resulting in the overprediction of missense alterations as deleterious. Therefore, it is not recommended that these in-silico predictions could be used as the sole source of evidence to make a clinical assertion [12].

DHT-dependent transcriptional induction of the androgen-regulated AP0D (apolipoprotein D) gene in fibroblasts was used to evaluate the function of the androgen receptor [13], but the invasiveness limited the application, and it was not helpful to illustrate the functional defects of the variants when next-generation sequencing (NGS) was widely used in the molecular diagnosis. The present study described the clinical features and molecular basis of 36 Chinese 46, XY DSD patients with AR variants that were identified using targeted NGS and investigated the functional alterations of eight novel AR variants in vitro.

Materials and methods

Patients

150 Chinese 46, XY DSD patients, who visited our hospital from 2009 to 2019 and could not be diagnosed according to the typical clinical phenotypes and routine candidate gene strategies, were recruited for this study. The phenotypes of these patients ranged from different degrees of undermasculinization to a nearly complete female appearance. The Ethics Committee (Institutional Review Board) of the Ninth People’s Hospital of Shanghai approved all protocols. Patients provided written informed consent.

Next-generation sequencing and data analysis

A total of 80 related genes were selected in the NGS panel (Additional file 1: Table S1) [3]. Genomic DNA of 150 patients was extracted from peripheral blood lymphocytes and genomic sequences were obtained from the University of California, Santa Cruz and National Center for Biotechnology Information databases. We completed the targeted exome design and capture by using the Access Array system and Illumina Sequencing System (Fluidigm, San Francisco, CA, USA). The entire coding regions and exon–intron boundaries of the genes were amplified by multiplex PCR on the Access Array™ microfluidics platform (Fluidigm, San Francisco, CA, USA) [3]. Variants with a frequency of < 1% were retained and ultimately confirmed by Sanger sequencing. Targeted, capture-based DNA sequencing was used in patient 36, who showed classical CAIS, but found no mutation by above-mentioned method.

Assessment of variants

According to the guidelines published by the American College of Medical Genetics and Genomics (ACMG), the variants were classified into five categories: pathogenic, likely pathogenic, variants of uncertain clinical significance (VUS), likely benign and benign [12]. Novel AR variants were predicted to be damaging or not by in-silico analyses [3]. Because the well-established in vitro functional study is one of the strong levels for assessing the pathogenicity of variants (PS3 and BS3), all the novel AR variants were reclassified after in vitro functional assays [12].

Clinical data

Thirty-six subjects with identified AR variants were enrolled for further study. The clinical data were collected at the subjects’ first visit to our hospital without any medication, however, patients 5 and 9 had already undergone ‘inguinal hernia surgery’. External masculinization score (EMS) was calculated to obtain a quantitative measure of the degree of undermasculinization [14]. Serum T, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels were measured using chemiluminescent immunoassays (Abbott Diagnostics, Abbott Park, IL, USA), and serum anti-Mullerian hormone (AMH) was measured by electrochemiluminescence immunoassay (Roche, Switzerland). The androgen
sensitivity index (ASI), which is frequently higher in individuals with AIS, was defined as the product of LH and T: 
ASI = LH (mIU/ml) \times T (ng/ml) [15]. All the AIS patients were divided into CAIS and PAIS subgroups according to the clinical phenotype.

**Plasmid construction**

pCMV-hAR-WT and pRL-SV40 were kindly provided by Dr. Shigeaki Kato (University of Tokyo, Tokyo, Japan). p(ARE)4-Luc, which contains four synthetic tandem repeats of an androgen-responsive element (ARE), was a kind gift from Dr. Xin Yuan from Beth Israel Deaconess Medical Center, Harvard Medical School. Wild-type (WT) human AR cDNA was amplified from pCMV-hAR by PCR using specific primers with restriction enzyme sites (Xho I-BamH I) and subsequently cloned into the expression vector pEGFP-N2 to generate pEGFP-N2-AR-WT (the primers are presented in Additional file 1: Table S2).

**Site-directed mutagenesis of AR**

Eight mutant AR expression vectors carrying the novel variants, including c.368_369 ins T, p.L295P, p.A588P, p.G590R, p.R761W, p.L812Q, p.F879C, and p.I907V, were created by site-directed mutagenesis (TRANSGEN Biotech, China) using pCMV-hAR-WT and pEGFP-N2-AR-WT as the templates respectively. The primers used for mutagenesis are listed in Additional file 1: Table S2. Before further functional studies, the entire coding sequences of all the mutant plasmids were confirmed by Sanger sequencing.

**Transcriptional assays**

Dimerized ARs translocate into the nucleus and bind to the ARE sequences found in various AR target genes to initiate a complex transcriptional program in target cells, such as LNCaP, the human prostate cancer cell line [16]. Transcriptional assays were performed in 24-well plates using Lipofectamine 2000 (1 μl/well) (Invitrogen, Waltham, MA, USA). Empty vector, WT and mutant AR expression vectors (200 ng/well) were cotransfected into LNCaP cells with p(ARE)4-Luc (200 ng/well) and pRL-SV40 (10 ng/well) containing Renilla luciferase as an internal indicator. After 24 h, the LNCaP cells were incubated in RPMI 1640 containing 10% dextran-coated charcoal-stripped fetal bovine serum and 10⁻⁷ M DHT.

To eliminate the possible influence of the LNCaP cell line or DHT concentration on the functional activity of mutant ARs with p.L295P, transcriptional assays were repeated under the same conditions but in the embryonic kidney (HEK) 293T cells incubated with Dulbecco’s modified Eagle’s medium containing 10% FBS containing 10⁻⁷ M, 10⁻⁶ M or 10⁻⁵ M DHT for 24 h.

LNCaP and 293T cells were washed twice with PBS and lysed via incubation with Passive Lysis Buffer (100 μl/well, Promega Co., Madison, WI) for 20 min. The lysate (20 μl) in each well was sampled to measure the firefly and Renilla luciferase activities using the Dual-Luciferase Reporter assay system (Promega, Madison, WI, USA). The results were normalized to the internal Renilla control and presented as the relative luciferase activity. All the experiments were carried out in triplicate wells and repeated three times.

**Subcellular localization**

The pEGFP-N2 vector, pEGFP-N2-AR and 8 novel AR mutants were transfected into 293T cells in a confocal dish with Lipofectamine 2000 (5 μl). The cells were incubated with 10⁻⁷ M DHT except for one dish transfected with WT AR. The medium was removed after 24 h. The cells were washed three times with PBS and fixed with 4% paraformaldehyde for 15 min. Nuclear counterstaining was performed with Hoechst (Hoechst AG, Frankfurt, Germany) for 5 min, and images were obtained by confocal laser scanning microscopy (Nikon A1, Japan).

**Statistical analysis**

Data are presented as medians with interquartile range. The Mann–Whitney U test was performed for comparisons of hormone levels between CAIS and PAIS patients and for AR functional assays using GraphPad Prism 8.0 software (GraphPad Software, San Diego, CA, USA). A two-sided P value < 0.05 indicated a significant difference.

**Results**

**AR variant analysis**

From the 150 subjects, a total of 23 variants of the AR gene were identified in 36 patients from 31 unrelated families (Table 1). Eight variants, including c.368_369 ins T (producing a truncated protein of 156 amino acids), p.L295P, p.A588P, p.G590R, p.R761W, p.L812Q, p.F879C and p.I907V, were novel (Table 1). Eight variants, including c.368_369 ins T, all the amino acid residues of novel variants were conserved during evolution (Fig. 1). One PAIS patient exhibited the somatic mosaicism of an AR mutation. Seven unrelated patients (19.4%) harbored missense mutations at codon 841, with different amino acid changes (p.R841C or p.R841H). Patient 20 had 2 different missense AR mutations (p.P392R and p.P841C). Patient 36 was observed to have large deletion from exon 2 to exon 8 of AR by capture-based NGS. Moreover, 30.6% (11/36) of patients carried more than 2 variants other than AR, especially patient 3, who harbored variants in four other related genes (Table 1).
| No | cDNA     | Protein | Functional domain | SIFT | Poly Phen2 | Mutation taster | ACGM classification | Other gene mutations | Definite diagnosis |
|----|----------|---------|------------------|------|-----------|----------------|---------------------|----------------------|----------------------|
| 1  | c.2719 A>G | p.I907V | LBD              | T    | B         | DC             | VUS                 | Likely pathogenic   | N                    | PAIS                |
| 2  | c.2719 A>G | p.I907V | LBD              |      |           |                | N                   | PAIS                |
| 3  | c.2636T>G | p.F879C | LBD              | Dele | D         | DC             | VUS                 | Likely pathogenic   | DGKK, p.A106T(c.316 C>T), EGF p.I6V(c.16 A>G), FKBP4 p.L356F(c.1066 C>T), GA4 p.R243W(c.727 C>T) | PAIS |
| 4  | c.2636T>G | p.F879C | LBD              |      |           |                | N                   | PAIS                |
| 5  | c.1762 G>C | p.A588P | DBD              | Dele | D         | DC             | VUS                 | Likely pathogenic   | N                    | CAIS                |
| 6  | c.1762 G>C | p.A588P | DBD              |      |           |                | N                   | CAIS                |
| 7  | c.1762 G>C | p.A588P | DBD              |      |           |                | N                   | CAIS                |
| 8  | c.1762 G>C | p.A588P | DBD              |      |           |                | N                   | CAIS                |
| 9  | c.2435T>A | p.L812Q | LBD              | Dele | D         | DC             | VUS                 | Likely pathogenic   | BMP4 p.R269Q(c.806 C>T), POR p.G625G(c.1876 G>A), MAP3K1 p.V889L(c.2665 G>C) | PAIS |
| 10 | c.1768 G>C | p.G590R | NTD(Tau-1)       | Dele | D         | DC             | VUS                 | Likely pathogenic   | N                    | CAIS                |
| 11 | c.2281 A>T | p.R761W | LBD              | Dele | D         | DC             | VUS                 | Likely pathogenic   | N                    | PAIS                |
| 12 | c.368_369 ins T | c.368_369 ins T |   |      |           |                | N                   | CAIS                |
| 13 | c.884T>C | p.L295F | NTD(Tau-1)       | Dele | D         | DC             | VUS                 | Likely benign       | N                    | NRSA1               |
| 14 | c.1822 C>T | p.R608X | A                 |      |           |                | Pathogenic          | N                    | CAIS                |
| 15 | c.2667 C>T | p.S889S | LBD              |      |           |                | Likely benign       | SRD5A2 p.V89L(c.264 G>C) (SNP) | PAIS |
| 16 | c.2667 C>T | p.S889S | LBD              |      |           |                | N                   | PAIS                |
| 17 | c.2521 C>T | p.R841C | LBD              | Dele | D         | A              | Likely pathogenic   | CBX2 p.G185E(c.554 G>A) | PAIS |
| 18 | c.2521 C>T | p.R841C | LBD              |      |           |                | N                   | PAIS                |
| 19 | c.2521 C>T | p.R841C | LBD              |      |           |                | N                   | PAIS                |
| 20 | c.1175 C>G c.2521 C>T | p.P392R; p.R841C | NTD(Tau-5), LBD | Dele | D         | DC             | VUS                 | ESR1 p.P146Q(c.437 C>A) | PAIS |
| 21 | c.2522 G>A | p.R841H | LBD              | Dele | D         | A              | Likely pathogenic   | N                    | CAIS                |
| No | cDNA       | Protein | Functional domain | SIFT | Poly Phen2 | Mutation taster | ACGM classification | Other gene mutations | Definite diagnosis |
|----|------------|---------|-------------------|------|------------|-----------------|---------------------|---------------------|-------------------|
| 22 | c.2522 G>A | p.R841H | LBD               | T    | B          | DC              | Likely pathogenic   | N                   | PAIS              |
| 23 | c.2522 G>A | p.R841H | LBD               | T    | B          | DC              | Likely pathogenic   | N                   | PAIS              |
| 24 | c.2437 C>T | p.L813F | LBD               | T    | B          | DC              | Likely pathogenic   | N                   | PAIS              |
| 25 | c.2437 C>T | p.L813F | LBD               | T    | B          | DC              | Likely pathogenic   | N                   | PAIS              |
| 26 | c.528 C>A  | p.S176R | NTD(Tau-1)        | Dele | D          | DC              | VUS                 | POR p.E119Q(c.357 G>C),GJA4 p.R243W(c.727 C>T) | PAIS              |
| 27 | c.528 C>A  | p.S176R | NTD(Tau-1)        |      |            |                 |                     | N                   | PAIS              |
| 28 | c.2612 C>T | p.A871V | LBD               | T    | B          | DC              | Likely pathogenic   | BMP7 p.T251M(c.752T) | PAIS              |
| 30 | c.2057 T>C | p.V686A | LBD               | T    | B          | DC              | VUS                 | N                   | PAIS              |
| 31 | c.2227 A>G | p.M743V | LBD               | Dele | P          | DC              | VUS                 | PHF6 p.N1475(c.440A>G) | PAIS              |
| 32 | c.2710 G>A | p.V904M | LBD               | Dele | P          | DC              | VUS                 | N                   | CAIS              |
| 33 | c.1846 C>G | p.R616G | DBD               | Dele | D          | DC              | Likely pathogenic   | N                   | PAIS              |
| 34 | c.2104 C>T | p.L702F | DBD               | Dele | D          | DC              | Likely pathogenic   | N                   | CAIS              |
| 35 | c.1739 G>T | p.C580F | DBD               | Dele | D          | A               | Likely pathogenic   | N                   | PAIS              |
| 36 | exon 2–8 del |        |                   |      |            |                 |                     | BMP2 p.R131S(c.395T) | CAIS              |

LBD ligand-binding domain, DBD DNA-binding domain, NTD N-terminal domain, Tau transcription activation units, SIFT Sorting Intolerant From Tolerant, T tolerated, Dele deleterious, B benign, D probably damaging, P possibly damaging, DC disease causing, A disease causing automatic, ACMG American College of Medical Genetics and Genomics, VUS variant of uncertain significance, PAIS partial androgen insensitive syndrome, CAIS complete androgen insensitive syndrome, NR5A1 nuclear receptor subfamily 5 Group A member 1

a) Novel mutation

b) Mosaic mutation
Clinical features
The clinical features of the patients were presented in Additional file 1: Table S3. Thirty-six patients, aged 0.9 year to 62 years, presented various phenotypes of undermasculinization, such as microphallus or clitoromegaly, which was the most frequent symptom observed in this cohort.

According to the phenotype, AIS patients were divided into two subgroups, the CAIS (n = 11) and PAIS (n = 24) group. All the CAIS patients were reared as females. Sixteen patients in the PAIS group were raised as male, six were reared as females, and two patients underwent gender reassignment after puberty. Gynecomastia was found in 95% (21/22) of postpubertal patients with AIS. Patients 5 and 9 underwent ‘inguinal hernia surgery’ (orchiectomy) before their first visit to our hospital. Thirteen patients had a family history of similar clinical presentation.

The serum levels of FSH, LH, T and AMH and the ASI are presented in Additional file 1: Table S3. FSH levels (18.8 [8.6, 48.7] vs. 5.5 [3.3, 9.3]; P < 0.05) and Serum LH (26.3 [19.2, 37.2] vs. 11.1 [7.1, 12.6]; P < 0.01) were significantly higher and EMS was significantly lower (P < 0.05) in postpubertal patients with CAIS than those in patients with PAIS (Fig. 2a, b and Additional file 1: Table S4). However, no significant differences were observed in serum concentrations of T (10.3 [4.6, 14.0] vs. 16.1 [11.6, 22.8]; P > 0.05) or ASI (214.8 [105.3, 447.9] vs. 157.7 [90.1, 240.4]; P > 0.05) between the CAIS and PAIS groups (Fig. 2c and Additional file 1: Table S4).

AR in vitro functional assays
After exploring the concentrations of DHT, we performed the assay with incubation of 10^{-7} M DHT to obtain the adequate transcriptional activity of AR in vitro (Additional file 2: Supplemental Fig. 1). All the novel mutant receptors exhibited markedly impaired transcriptional activity in the functional assays compared to that in cells transfected with wild-type AR (P < 0.05), except p.L295P (Fig. 3a). This mutation was detected in a 19-year-old patient whose clinical features were not similar to typical AIS. This patient showed a relatively developed penis (length of 4 cm), no gynecomastia, extremely elevated serum LH (51.33 mIU/ml) and FSH (79.94 mIU/ml) levels, relatively lower T (2.8 ng/ml, normal range 1.42–9.23 ng/ml) level and significantly reduced AMH level (0.44 ng/ml) (Additional file 1: Table S3). In the further assays in HEK 293T cells, mutant AR with p.L295P retained transcriptional activity similar to AR WT cultured with variant concentrations of DHT (Fig. 3b). Notably, the p.T29K mutation in the NR5A1 gene and the p.A1411T mutation in the MYH gene were identified in this patient (Table 1). The transcriptional activities in LNCaP cells transfected with p.A588P, p.G590R, p.R761W and p.L812Q variants were significantly
reduced, similar to those in cells transfected with empty vector ($P > 0.05$) (Fig. 3a).

GFP-tagged WT ARs showed nuclear localization with a uniform distribution. A similar nuclear localization pattern was observed for the seven novel missense mutants (p.L295P, p.A588P, p.G590R, p.R761W, p.L812Q, p.F879C and p.I907V). However, the AR mutant c.368_369 ins T showed a distinct cytoplasmic localization pattern, similar to those in cells transfected with empty vector ($P > 0.05$) (Fig. 3a).

**Fig. 2** The scatterplot of the serum hormones for postpubertal patients with CAIS and PAIS except for patient 5, 9 and 12. **a** The scatterplot of follicle-stimulating hormone (FSH). **b** The scatterplot of luteinizing hormone (LH). **c** The scatterplot of testosterone (T). CAIS ($n = 11$); PAIS ($n = 24$); *$P < 0.05$.

**Fig. 3** The transcriptional activities of WT and mutant AR were investigated using the androgen response element (ARE) promoter. The relative luminescence activity was expressed as a ratio of firefly to Renilla luciferase. **a** WT and all of the novel mutant AR in LNCaP cells. **b** WT AR, p.L295P, and p.A588P (as positive control) in 293T cells cultured with variant concentrations of DHT. The error bars represent the standard error. *versus WT $P < 0.05$; # versus Vector $P > 0.05$. 

---

**Fig. 2**

- **a** The scatterplot of follicle-stimulating hormone (FSH).
- **b** The scatterplot of luteinizing hormone (LH).
- **c** The scatterplot of testosterone (T).

**CAIS** ($n = 11$), **PAIS** ($n = 24$); *$P < 0.05$.

**Fig. 3**

- **a** ARE promoter in LNCaP cells.
- **b** ARE promoter in 293T cells.

**AR plasmid**

- DHT concentration $10^{-7}$M

**AR plasmid**

- DHT concentration

---

* Versus WT $P < 0.05$; # Versus Vector $P > 0.05$. 
localization, which suggests impaired nuclear translocation (Fig. 4).

**Pathogenicity prediction of AR variants**

All the novel AR variants were initially predicted to be VUS. However, according to the guideline of ACMG, based on the results of in vitro functional assays (PS3) and absence from controls in 1000 Genomes Project (PM2), all of the novel variants were reclassified as likely pathogenic except P.L295P. This variant met ‘Well-established in vitro functional studies show no damaging effect on protein function’ and ‘Variant found in a case with an alternate molecular basis for disease’ (BS3 and BP5) and was reclassified as likely benign, despite it was also predicted to be damaging by SIFT, Polyphen-2 and MutationTaster analysis (Table 1) [12]. Mutation c.368_369 ins T was reclassified as pathogenic according to ACMG guideline (PVS1 + PS3).

**Discussion**

Due to similar clinical manifestations, it is difficult to distinguish AIS, especially PAIS, from other causes of 46, XY DSDs, such as partial gonadal dysgenesis and
5α-reductase 2 deficiency [7]. The typical serum hormone profile of pubertal AIS patients is characterized by an elevated or normal basal T level, an increased LH level, and a high ASI but a normal or mild elevated FSH level, which is also recommended for the selection of atypical subjects for analyses of the AR gene [15, 17, 18]. Melo et al. [18] found no significant differences in serum LH, FSH, DHT or T levels between patients with CAIS and PAIS. In the present study, we found that serum LH and FSH levels of the Chinese postpubertal patients with CAIS were significantly higher than those of postpubertal PAIS patients ($P<0.05$) (Fig. 2).

A severe AIS phenotype may be related to LBD mutations, especially mutations between amino acid residues 688–712, 739–784 or 827–870, which comprise the greater part of the ligand-binding pocket [1]. Accordingly, 66.7% (6/9) of our patients harboring the mutations located in these regions presented with more severe phenotypes (EMS 2–3), except three patients (patients 17, 19 and 20, EMS 5.5–8) with p.R841C, which was previously found in male individuals with preserved fertility and reached an increased N/C interaction at higher T or various DHT concentrations in vitro [18, 19]. Herein, 19.4% of unrelated patients harbored AR mutations at the same residue (three with p.R841H and four with p.R841C), suggesting the Arg 841 residue is a mutation ‘hotspot’ in Chinese AIS patients.

The correlations between genotype and phenotype were not clarified in AIS patients [6, 11, 15, 20]. Oligogenicity, somatic mosaicism and AR coregulators (activators and repressors) may contribute to the variation of phenotypes [21–23]. In the present study, 30.6% of the patients had variants in more than 2 related genes using targeted NGS (Table 1). Notably, some of these sequenced genes were associated with human DSD, such as SRD5A2 mutations causing 5α-reductase type 2 deficiency and variants in the CBX2 gene reported in prenatal 46, XY phenotypic females [24, 25]. However, it does not mean that patients with more mutations in different genes manifested more severe symptoms in this cohort, such as patient 3 (EMS = 6), who harbored variants in four other related genes. Although rarely described in AIS, somatic mosaicism may also contribute to the variation in AIS phenotypes [21]. In our study, four novel mutations exhibited a complete loss of androgen-induced transcriptional activity (Fig. 3a). In accordance with this result, six patients with p.L812Q, p.A588P or p.R761W exhibited a severe phenotype (EMS = 2). However, patient 10, containing p.G590R and three more variants in other related genes, presented a mild clinical feature (EMS = 7), in whom the somatic mosaicism of AR mutation was detected (Table 1 and Additional file 1: Table S3).

So far AR mutation has been considered as the confirmed cause for AIS, although it was not found in all patients clinically diagnosed with AIS [4]. The reduced AR mRNA expression in genital skin-derived fibroblasts, single-nucleotide polymorphisms (SNPs) paralleled by reduced AR expression, mutations outside the AR coding sequence, and variants in AR cofactors crucial for proper AR activity were also presumed potential causes [5, 13, 26]. Therefore, the impaired function of AR, rather than the AR mutations themselves, causes AIS. However, most of the reported AR mutations detected in DSD patients were predicted to be pathogenic or likely pathogenic via in silico tools instead of functional assays in vitro. In general, most algorithms are 65–80% accurate for missense variant prediction when examining known disease variants [12]. According to the guideline of ACMG, well-established in vitro functional studies (PS3 and BS3) may reclassify the variants. In a previous study, 61 SCN5A variants initially predicted as VUS by in-silico analyses were reclassified as benign/likely benign (n = 14), likely pathogenic (n = 35) and still VUS (n = 12) via high-throughput automated patch clamping [27]. In our study, it was found that all the novel AR variants, which were initially predicted to be VUS, significantly impaired the transcriptional activity of AR and were reclassified as pathogenic/likely pathogenic, except p.L295P (Table 1 and Fig. 3a). In rare cases, AR mutations have no influence on AR function in vitro, such as p.P392R (p.P390R using the former numbering system) [28], similar to p.L295P found in our patient 20, which is also located in an important region for transcriptional activity within the NTD [9, 10] and was predicted to be a VUS in-silico. This mutation was first reported in a CAIS patient with three different AR mutations (p.P392R, p.Q445R and p.E213E) [28]. However, p.P392R, neither independently nor in combination with p.Q445R, revealed any androgen-binding or transcription activation abnormality in vitro [28]. Another mutation at the same amino acid residue (p.P392S) was reported in two unrelated individuals with oligospermia and did not lead to alterations of AR transcriptional activity in vitro, either [15]. In a CAIS patient with two AR mutations (p.Q799E and p.C807F), in vitro assays showed that these two mutations impaired AR function and exerted a synergistic negative effect on the AR transcriptional ability in combination [8, 15]. Unlike this patient, subject 18 exhibited a milder clinical phenotype (EMS = 7) despite harboring two different AR mutations (p.P392R and p.R841C), which was consistent with the results of the transcriptional assays of these two mutations in vitro.

To eliminate the possibility of potential interference, we repeated the transcriptional assays of p.L295P in HEK 293T cell system. Consistently, mutant ARs with p.L295P maintained normal transcriptional activity similar to the
WT AR protein, even with various DHT concentrations (Fig. 3b). Previous studies showed that serum AMH was abnormally increased in CAIS children and remained at an extremely high level in postpubertal patients with CAIS because of the dysfunctional ARs in normal Sertoli cells [29]. However, patient 13 with p.L295P presented an obviously different serum hormone profile, including a relatively lower T level, an extremely elevated serum FSH level and a drastically reduced AMH level (Additional file 1: Table S3). Gynecomastia, which is one of the indicators of AIS, even MAIS [17], was also absent from this patient. We revealed two additional variants in this patient, p.T29K of NR5A1 and p.A1411T of MYH, by targeted NGS (Table 1). The NR5A1 gene encodes steroidogenic factor 1, which is essential for sexual differentiation and formation of the primary steroidogenic tissues [30]. Our previous study found that p.T29K mutation altered subnuclear structure and impaired the transactivation ability of NR5A1 in vitro [3]. Therefore, all the clinical features of patient 13, including the extremely reduced AMH level, the lack of gynecomastia and a comparatively developed penis, especially under the effects of a relatively low T concentration, may be explained by the dysfunction of the NR5A1 gene resulting from the mutation p.T29K and suggested the improper diagnosis of PAIS in this patient. AR variant p.L295P was also reclassified as likely benign due to the criteria BS3 and BP5.

In conclusion, 23 AR variants were identified in 36 Chinese 46, XY DSD patients by using targeted NGS. Out of eight novel variants initially predicted as VUS, seven were reclassified as pathogenic/likely pathogenic and one was reclassified as likely benign due to the results of in vitro functional assays. In Chinese patients with AIS, amino acid residue Arg841 was one of the mutation hotspots in the AR gene, and the higher LH and FSH levels may be indicative of CAIS postpuberty. AR variants may not significantly impair AR function in some cases, which suggests the importance of functional assays, instead of in-silico analyses, especially in patients with multiple gene variants.

**Abbreviations**

AIS: Androgen insensitive syndrome; AR: Androgen receptor; DSD: Disorder/ differences of sex development; NGS: Next-generation sequencing; CAIS: Complete androgen insensitive syndrome; PAIS: Partial androgen insensitive syndrome; MAIS: Mild androgen insensitivity syndrome; T: Testosterone; DHT: Dihydrotestosterone; NTD: N-terminal domain; DBD: DNA-binding domain; LBD: Ligand-binding domain; Tau: Transcription activation units; APOD: Apolipoprotein D; SNPs: Single-nucleotide polymorphisms; ACMG: American College of Medical Genetics and Genomics; VUS: Variants of uncertain clinical significance; EMS: External masculinization score; LH: Luteinizing hormone; FSH: Follicle-stimulating hormone; AMH: Anti-Mullerian hormone; ASI: Androgen sensitivity index; ARE: Androgen-responsive element; WT: Wide-type; HEK: Human embryonic kidney.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13023-021-01765-w.

**Additional file 1.** Supplemental tables for related genes, primers and clinical data.

**Additional file 2: Supplemental Fig. 1.** The influence of DHT concentration in AR functional assays in vitro. The transcriptional assay was investigated with WT AR plasmid and androgen response element (ARE) promoter. The transfected LNCap cells were incubated with 0.1% dimethyl sulfoxide (DMSO, as negative control) or variable concentrations of DHT. The relative luminescence activity was expressed as a ratio of firefly to Renilla luciferase. The error bars represent the standard error. *, vs 0.1% DMSO P < 0.05; #, vs 10^{-7} M DHT P > 0.05

**Acknowledgements**

We are grateful to the patients and their families for their supports and participation in this study.

**Authors’ contributions**

H.Z., H.Y., X.Y. and Y.C. contributed equally to this work. N.W., H.W. and S.Z. performed the targeted exome sequencing, sequencing data analysis and prediction of variants. Verification by Sanger sequencing was performed by Y.X., H.Z., B.H., N.W., H.W., W.Z. and Y.S. The serum AMH levels were measured by Q.Z. Cell culture experiments and functional assays were completed by H.Z., H.Y., Y.C., H.S., H.Z., Y.X., H.W., W.Z. and Y.S. performed recruitment of patients, collected, and interpreted clinical data. H.Z. and Y.C. did the statistical analysis. Y.L. and J.Q. conceived and designed the experiments. H.S., Y.L. and J.Q. revised the manuscript. All authors have seen and approved the final manuscript.

**Funding**

This work was supported by the grants from the National Natural Science Foundation of China (Grant Number: 81873652, 81670717, 81570753) and Clinical Research Project of Multi-Disciplinary Team, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine (201903).

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The Ethics Committee (Institutional Review Board) of the Ninth People’s Hospital of Shanghai approved all protocols. Patients provided written informed consent.

**Consent for publication**

All authors agreed on the manuscript.

**Competing interests**

The authors declare that they have no conflict of interest.

**Author details**

1. Department of Endocrinology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. 2. Department of Urology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. 3. Department of Obstetrics and Gynecology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. 4. Research Centre for Clinical Medicine, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. 5. Department of Plastic Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.

Received: 13 December 2020   Accepted: 25 February 2021

Published online: 09 March 2021
References

1. Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyanni-Elia K, MacDougall J. Androgen insensitivity syndrome. Lancet. 2012;380(9851):1419–28.

2. Audi L, Fernandez-Cancio M, Carrascosa A, Andaluz P, Toran N, Piro C, et al. Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46, XY disorder of sex development. J Clin Endocrinol Metab. 2010;95(4):1876–88.

3. Wang H, Zhang L, Wang N, Zhu H, Han B, Sun F, et al. Next-generation sequencing reveals genetic landscape in 46, XY disorders of sexual development patients with variable phenotypes. Hum Genet. 2018;137(3):265–77.

4. Gulia C, Baldassarria S, Zangari A, Briganti V, Gigli S, Gaffi M, et al. Androgen insensitivity syndrome. Eur Rev Med Pharmacol Sci. 2018;22(12):3873–87.

5. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28(7):778–808.

6. Mendonca BB, Domenice S, Arnhold IU, Costa EM. 46, XY disorders of sex development (DSD). Clin Endocrinol (Oxf). 2009;70(2):173–87.

7. Batista RL, Costa EMF, Rodrigues AS, Gomes NL, Faria JA Jr, Nishi MY, et al. Androgen insensitivity syndrome: a review. Arch Endocrinol Metab. 2018;62(2):227–35.

8. Petroli RJ, Hiort O, Struve D, Gesing JK, Soardi FC, Spinola-Castro AM, et al. Functional impact of novel androgen receptor mutations on the clinical manifestation of androgen insensitivity syndrome. Sex Dev. 2017;11(5–6):238–47.

9. MacLean HE, Wada Y, Li B, Muhammad A, Kalash OR, O'Neill MJ, et al. Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-Mullerian hormone repression during early human testis development (DSD). Semin Cell Dev Biol. 2015;45:77–83.

10. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev. 2001;81(3):1269–304.

11. Touzon MS, Garrido NP, Marino R, Ramirez P, Costanzo M, Guercio G, et al. Androgen insensitivity syndrome: clinical phenotype and molecular analysis in a single tertiary center cohort. J Clin Res Pediatr Endocrinol. 2019;11(1):24–33.

12. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.

13. Horning NC, Ukat M, Schweikert HU, Hiort O, Werner R, Drop SL, et al. Identification of an AR mutation-negative class of androgen insensitivity by determining endogenous AR activity. J Clin Endocrinol Metab. 2016;101(11):4468–77.

14. Ahmed SF, Khwaja O, Hughes IA. The role of a clinical score in the assessment of ambiguous genitalia. BJU Int. 2000;85(12):120–24.

15. Hiort O, Holterhus PM, Horter T, Schulze W, Kremke B, Bals-Pratsch M, et al. Significance of mutations in the androgen receptor gene in males with idiopathic infertility. J Clin Endocrinol Metab. 2000;85(8):2810–5.

16. Shukla GC, Plaga AR, Shankar E, Gupta S. Androgen receptor-related diseases: what do we know? Andrology. 2016;4(3):366–81. https://doi.org/10.1111/andr.12167 (Epub 2016 Mar 16).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more at: biomedcentral.com/submissions